1. Scrip
  2. >>New Products

Eisai Forecasts Surging Leqembi Sales In Its New Fiscal Year

Launch Progresses In US, Japan And Beyond

 
• By Mandy Jackson

Eisai expects growth to JPY56.5bn ($364.7m) in fiscal year 2024 from JPY4.3bn ($27.8m) in FY 2023. The company initiated a rolling BLA submission for subcutaneous Leqembi as maintenance therapy and expects approval in 2025.

Rapid growth of economic indicators. rapid growth of financial indicators of economy. economic and financial growth.
Leqembi growth will come largely from US sales, but also from Japan and other countries • Source: Shutterstock

Eisai Co., Ltd.'s most closely watched drug – the anti-amyloid antibody Leqembi (lecanemab) – contributed little revenue in the fiscal year that ended on 31 March, but the Japanese big pharma expects a big ramp up in the new year. 

The firm reported JPY741.8bn ($4.79bn) in fiscal year 2023 revenue, essentially flat relative to FY 2022 revenue of JPY744.4bn ($4

Key Takeaways

  • Eisai reported JPY4.3bn ($27.8m) in fiscal year 2023 Leqembi sales and expects the early Alzheimer’s treatment to generate JPY56.5bn ($364.7m) in fiscal year 2024.

  • While most will come from US sales, Japan and other countries will contribute Leqembi revenue in the new fiscal year, ending 31 March 2025

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Scrip

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.